ILMN: All proposals were preliminarily approved, with no questions raised during the Q&A session
During Illumina, Inc.'s 2026 Annual General Meeting, all proposals, including director elections, auditor ratification, and executive compensation, received preliminary approval. No questions were submitted during the Q&A session. The information is based on the AGM audio transcript, with forward-looking statements subject to SEC filings.
DNA Methylation Sequencing Market to Reach USD 5.49 Billion
The global DNA Methylation Sequencing Market is projected to grow from USD 1.80 billion in 2025 to USD 5.49 billion by 2033, demonstrating a CAGR of 15.6%. This growth is fueled by increasing epigenetics research, rising prevalence of cancer and genetic disorders, and the growing adoption of precision medicine technologies. North America is expected to hold 43.1% of the market share, driven by advanced genomic research infrastructure and significant investments in cancer epigenetics.
Illumina stock (US4523271090): corporate responsibility push after return to growth
Illumina has released its latest Corporate Responsibility Report, highlighting efforts in climate, inclusion, and genomic access, shortly after reporting a 4.8% year-over-year revenue increase in Q1 2026 to $1.09 billion. This marks a return to top-line growth and coincides with a strategic pivot towards clinically oriented applications like oncology diagnostics. The report emphasizes ESG considerations for investors and links them to the company's long-term resilience and competitive positioning in the genomics market.
Illumina stock (US4523271090): Corporate Responsibility Report highlights genomics growth drivers
Illumina's 2025 Corporate Responsibility Report emphasizes sustainability, expanded genomics access, and product innovation, while investors concurrently monitor demand for its sequencing platforms and cash generation. The report details significant reductions in product packaging and greenhouse gas emissions, alongside initiatives to broaden genomic access globally and commitments to ethical governance. These efforts, combined with strong operating cash flow of $1.08 billion for fiscal year 2025, position Illumina in the evolving genomic medicine ecosystem, amidst attention to ESG factors and market competition.
Is This the Right Time to Retain ILMN Stock in Your Portfolio?
Illumina Inc. (ILMN) is demonstrating strong progress with its long-term strategy, driven by growth in its core sequencing business, multiomics expansion, and software capabilities, with clinical demand being a key driver. Despite this positive momentum and a significant stock surge, the company faces headwinds from operations in China and broader macroeconomic pressures. Efforts to transition to NovaSeq X and focus on core genomics are promising, but challenges in the Chinese market and inflationary costs remain concerns.
Illumina stock (US4523271090): new responsibility report highlights growth drivers in genomics
Illumina's 2025 Corporate Responsibility Report details progress in sustainability, genomics access, and product innovation, alongside financial updates. The report highlights strong cash flow generation in fiscal year 2025 and new product launches like the 5-base solution and Illumina Protein Prep. For investors, the report and financial context provide insight into the company's strategic direction and its position in the evolving genomics market.
Illumina now sequences over 10 human genomes a minute, trims packaging 87%
Illumina has released its 2025 Corporate Responsibility Report, highlighting significant advancements in genomics access and sustainability. The company now sequences over 10 human genomes per minute and has reduced product packaging by 87% since 2019, surpassing its 2030 target. Additionally, Illumina achieved a 74% reduction in Scope 1 and 2 greenhouse gas emissions and maintained 100% renewable electricity for four consecutive years.
Illumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impact
Illumina has released its 2025 Corporate Responsibility Report, detailing its progress in making genomic medicine more accessible and its commitment to sustainability. The report highlights achievements such as expanding genomic access globally, reducing its environmental footprint, and significant contributions to STEM education and community engagement. Illumina aims to integrate genomics at scale to address global health challenges like cancer and rare diseases.
Illumina stock (US4523271090): gene sequencing player in focus after leadership and strategy updates
Illumina remains a key player in the genomics sector, especially after divesting GRAIL and implementing leadership and strategy changes. The company's business model is centered on providing DNA sequencing platforms and consumables, employing a "razor-and-blades" approach to generate recurring revenue. Illumina's focus is on expanding its installed instrument base and driving consumables sales across various research and clinical applications, positioning itself as an enabler of precision medicine.
Illumina Insider Sold Shares Worth $47,931,975, According to a Recent SEC Filing
An insider at Illumina (ILMN) recently sold shares valued at $47,931,975, as disclosed in a recent SEC filing. This transaction was reported by MT Newswires, highlighting significant insider activity for the genomic sequencing company. Further details regarding the specific insider or reasons for the sale were not provided in this brief announcement.
Illumina director Keith Meister sells $47.9m in shares
Illumina director Keith A. Meister sold approximately $47.9 million worth of shares over May 13 and May 14, 2026, through indirect holdings. These sales occurred as Illumina's stock traded near its 52-week high, following a significant 106% gain over the past year. Concurrently, transactions involving the partial termination of equity swaps also took place, affecting his beneficial ownership of the company.
Corvex Funds tied to Illumina (NASDAQ: ILMN) sell shares and partly unwind equity swaps
Corvex Funds, advised by Corvex Management LP and associated with Keith Meister, recently sold 329,460 shares of Illumina common stock and partially unwound equity swaps representing 255,378 notional shares. These transactions, primarily occurring on May 13-14, 2026, involved sales at weighted average prices between $144 and $148 per share, while the equity swap termination resulted in a payment to Corvex based on Illumina's market price. After these activities, the Corvex Funds indirectly hold 3,500,048 Illumina shares, and remaining equity swaps for 24,562 notional shares are set to expire in February 2028.
[SCHEDULE 13G/A] ILLUMINA, INC. Amended Passive Investment Disclosure
Capital World Investors (CWI) has filed an amended Schedule 13G/A for Illumina, Inc. (ILMN), disclosing beneficial ownership of 15,776,452 shares, which represents 10.3% of the outstanding common stock. This filing indicates that CWI has sole voting power over 15,688,387 shares and sole dispositive power over all 15,776,452 shares. The document clarifies the investment management structure and lists affiliated entities under Capital World Investors.
Daiwa Securities Upgrades Illumina to Outperform From Neutral, Adjusts Price Target to $155 From $128
Daiwa Securities has upgraded its rating for Illumina (ILMN) from Neutral to Outperform and increased its price target to $155 from $128. The upgrade signals a more positive outlook for the company's stock performance. This adjustment reflects analyst confidence in Illumina's future prospects.
Bioinformatics Platforms Market Is Going to Boom | • Illumina Inc • Thermo Fisher Scientific Inc • QIAGEN N.V
Worldwide Market Reports has released an in-depth study on the Bioinformatics Platforms Market, forecasting its size and trends from 2026-2033. The report, based on primary interviews and secondary data, analyzes growth drivers, opportunities, risks, and challenges, integrating SWOT and Porter's Five Forces analysis. It covers market segments by type, deployment mode, and application, and profiles key players like Illumina Inc., Thermo Fisher Scientific Inc., and QIAGEN N.V., providing regional coverage and strategic takeaways for decision-makers.
ILMN Stock Analysis 2026: Should You Invest in Illumina Now?
This article provides an analysis of Illumina (ILMN) stock in 2026, evaluating whether it's a wise investment. It highlights Illumina's leadership in genomic sequencing and its role in personalized medicine, while also discussing factors like market volatility, regulatory challenges, and competition. The piece aims to help investors make informed decisions by outlining the pros and cons of investing in ILMN stock.
Illumina (ILMN) Form 144 lists 600,000 shares with Goldman Sachs broker
Illumina, Inc. (ILMN) submitted a Form 144 filing reporting a proposed sale of 600,000 shares of common stock. Goldman Sachs & Co. LLC is identified as the broker for these open market transactions, which involved purchases made on October 25, 2023. The filing date is listed as May 13, 2026, and the shares have a par value of $0.01.
Illumina stock (US4523271090): Q1 2026 earnings beat signals recovery momentum
Illumina Inc. reported stronger-than-expected first-quarter 2026 results, with revenues of $1.091 billion and net income of $134 million, beating analyst estimates. This performance signals a recovery in demand for its genomics sequencing platforms and improved operational efficiency, despite prior competitive and regulatory hurdles. The earnings beat is expected to boost investor confidence in the company's leadership in the high-growth genomics sector.
The Bull Case For Illumina (ILMN) Could Change Following Upgraded 2026 Outlook And Major Buyback - Learn Why
Illumina recently reported strong Q1 2026 results, with revenue of US$1,091 million and net income of US$134 million, alongside increased EPS. The company also raised its full-year 2026 revenue guidance to US$4.52–US$4.62 billion and completed a significant share buyback, demonstrating management's confidence. This upgraded outlook and buyback could potentially alter the investment narrative, providing more visibility and supporting near-term earnings despite ongoing market challenges.
Illumina stock (US4523271090): Analyst consensus shifts to Hold amid mixed signals
Illumina Inc. (ILMN) stock closed at $142.51, up 0.44% on May 11, 2026, and has gained 8.7% year-to-date. However, analyst sentiment has shifted from bullish to a consensus Hold rating, with an average price target of $140.36, indicating the stock is potentially overvalued. Investors are advised to monitor upcoming earnings and clinical adoption trends given the mixed sentiment.
Illumina Inc. stock outperforms competitors on strong trading day
Illumina Inc. (ILMN) saw its stock rise by 2.24% to $145.70 on Tuesday, outperforming the broader market. This marked the third consecutive day of gains for the company, even as the S&P 500 Index experienced a slight decline. The Dow Jones Industrial Average, however, also saw a modest increase.
Illumina Inc. stock (US4523271090): Latest developments and business overview
Illumina Inc. remains a key player in the genomics sector, specializing in sequencing and array-based technologies vital for research and clinical applications. The company leverages a "razor-blade" business model, generating significant recurring revenue from high-margin consumables used with its widely adopted instruments like the NovaSeq series. Despite competition, Illumina holds a dominant market share in next-generation sequencing, making it a relevant investment for those seeking exposure to the growing life sciences market in the US.
SomaLogic stock (US82489T1043): Completed $350M sale to Illumina
Standard BioTools has finalized the sale of its SomaLogic subsidiary to Illumina for $350 million on January 30, 2026. This transaction strengthens Standard BioTools' financial position and supports its strategic focus on proteomics and multiomics technologies. SomaLogic, known for its SomaScan platform, was a key asset in the deal, enhancing Illumina's multiomics portfolio.
Corvex funds (NASDAQ: ILMN) exercise Illumina equity swaps, retain large position
Corvex funds, managed by director Keith A. Meister, partially terminated equity swaps referencing Illumina (NASDAQ: ILMN) shares. The funds acquired 88,804 common shares through in-the-money derivative exercises at a cost basis of $102.82 per share, and they retain swaps covering 279,940 notional shares. These transactions increased Corvex's reported indirect holdings to 3,909,076 common shares.
How Illumina employees work to move healthcare toward precision medicine
Illumina's Medical Affairs team is dedicated to advancing precision medicine by promoting genomic literacy, generating evidence, and overcoming barriers to genomic testing. This global team of over 30 experts, many with extensive clinical lab experience, educates healthcare providers, collaborates on research, and supports product development. Their work aims to integrate genomics into mainstream medicine, improve patient benefits, and address challenges such as complex data interpretation and reimbursement hurdles.
NovaSeq X software update v1.4 improves data quality and customer usability
Illumina has released software update v1.4 for its NovaSeq X Series, enhancing data quality and customer usability. Key improvements include flexible scheduling of sequencing runs, automatic detection of sample indices to reduce demultiplexing errors, and the introduction of new flow cell types and increased sequencing lengths. The update also delivers higher sequencing data quality, improved robustness for low-diversity applications, and an upgrade to DRAGEN v4.4 for enhanced secondary analysis.
Illumina stock (US4523271090): Q1 earnings beat lifts shares 8% YTD
Illumina reported better-than-expected Q1 2026 earnings, with adjusted EPS of $1.15 and revenue of $1.09 billion, exceeding analyst estimates. This performance contributed to an 8.2% year-to-date increase in its stock price, reaching $141.88 by May 8, 2026. The company maintains a strong position in the genomics market through its sequencing technologies and recurring revenue from consumables.
We Think That There Are Issues Underlying Illumina's (NASDAQ:ILMN) Earnings
Illumina's recent strong stock performance following its earnings report is scrutinized due to a significant portion of its profit coming from "unusual items." While these items boosted profit by US$213m over the last year, Simply Wall St suggests this might not be sustainable, potentially leading to a profit drop if not repeated. The analysis recommends investors look beyond statutory earnings to understand Illumina's true underlying profitability and consider other factors like return on equity and insider ownership.
Illumina Inc. stock (US4523271090): Earnings beat and momentum lift shares
Illumina Inc. shares have risen after the company exceeded quarterly earnings expectations, driven by renewed momentum in its core DNA sequencing business. The stock traded at approximately $141.88 on May 8, 2026, up about 8% from the start of the year, with Q1 2026 EPS of $1.15 beating the consensus estimate of $1.05. Analysts hold a mixed but cautiously positive sentiment, with an average price target around $140.36, recognizing both the company's strong market position and potential risks like regulatory scrutiny and competition.
Illumina Inc. stock outperforms competitors on strong trading day
Illumina Inc. (ILMN) stock advanced 2.29% to $141.88 on Friday, outperforming general market trends where the S&P 500 Index rose 0.84% and the Dow Jones Industrial Average rose 0.02%. The company's shares closed 8.78% below its 52-week high.
Illumina Inc. Stock (US4523271090): Analyst Ratings and Price Targets in Focus
This article focuses on analyst ratings and price targets for Illumina Inc. (ILMN), highlighting a mixed but generally constructive view from Wall Street. The average 12-month price target is approximately $111.95, suggesting moderate upside from current levels, though individual targets vary widely. The company's NovaSeq X platform and strategic shift towards clinical sequencing are key drivers, with projected mid-single-digit revenue growth over the medium term.
Illumina SVP Jakob Wedel Christensen sells $97,328 in stock
Jakob Wedel Christensen, Senior Vice President at Illumina, sold a total of 933 shares of company common stock for approximately $129,731 across two transactions on May 5th and 6th, 2026. Following these sales, he directly holds 15,056 shares. The sales occurred as Illumina's stock has seen a significant surge, returning 106% over the past year.
Illumina (NASDAQ: ILMN) SVP logs 700-share sale and 233-share tax withholding
Illumina's SVP, Strategy/Corp Development, Jakob Wedel Christensen, reported an open-market sale of 700 shares at $139.04 each on May 6, 2026, and a tax-withholding disposition of 233 shares at $139.07 each on May 5, 2026. Following these transactions, he directly holds 15,056 shares of Illumina common stock. The tax-withholding transaction was not a market sale but rather shares surrendered to cover tax obligations.
Illumina Inc. stock underperforms Thursday when compared to competitors
Illumina Inc. (ILMN) stock declined by 2.71% on Thursday, closing at $138.71, which was a day of overall poor performance for the stock market. The S&P 500 Index and Dow Jones Industrial Average also saw declines. This performance left Illumina Inc. shares 10.81% below their 52-week high.
Microfluidics Market Competitive Analysis to 2031 | Illumina, Inc, microfluidic ChipShop GmbH, Danaher etc.
The microfluidics market was valued at US$ 16.47 billion in 2021 and is projected to reach US$ 85.49 billion by 2031, growing at a CAGR of 17.9%. This growth is driven by the increasing shift towards point-of-care testing, rising demand for portable diagnostic devices, and advancements in personalized medicine and lab-on-a-chip systems. Key players like Danaher Corporation and Illumina, Inc. are focusing on innovation, with North America currently leading the market and Asia-Pacific expected to show the fastest growth.
[144] ILLUMINA, INC. SEC Filing
This article details an SEC Form 144 filing by ILLUMINA, INC. (ILMN) related to a proposed sale of 700 shares of common stock by an individual through Morgan Stanley Smith Barney LLC. The securities were acquired on May 5, 2026, as restricted stock from the issuer. The filing provides comprehensive information about the transaction, the filer, and the issuer, adhering to SEC disclosure requirements.
Whole Exome Sequencing Market key players 2024-2031: Illumina, Inc., Centogene AG, Eurofins Scientific etc
The global Whole Exome Sequencing (WES) market is projected to grow from US$ 414.5 million in 2023 to US$ 1,457.8 million by 2031, exhibiting a CAGR of 17.02%. This growth is driven by the rising prevalence of genetic diseases, the expansion of precision medicine, declining sequencing costs, and increasing applications in oncology and prenatal screening. North America currently dominates the market, with Asia-Pacific expected to show the fastest growth.
Illumina, Inc. (ILMN) Stock Analysis: Exploring Its 33.82% Return On Equity
Illumina, Inc. (ILMN) is capturing investor attention with its strong financial metrics, especially an impressive 33.82% Return on Equity, and strategic collaborations in the healthcare sector. The company, valued at $20.63 billion, shows efficient profit generation, solid revenue growth, and strong free cash flow, despite mixed analyst sentiment. Its focus on reinvestment and innovation in genomics suggests a long-term growth-oriented strategy.
Analysts Offer Insights on Healthcare Companies: Illumina (ILMN), Axsome Therapeutics (AXSM) and Kymera Therapeutics (KYMR)
Guggenheim analysts have reiterated bullish ratings on three healthcare companies: Illumina (ILMN), Axsome Therapeutics (AXSM), and Kymera Therapeutics (KYMR). Subbu Nambi maintained a Buy on Illumina with a $170 target, Yatin Suneja reiterated a Buy on Axsome Therapeutics with a $245 target, and Bradley Canino upheld a Buy on Kymera Therapeutics with a $125 target. All three stocks show significant upside potential based on analyst consensus.
Jennison Associates LLC Has $26.21 Million Stock Position in Illumina, Inc. $ILMN
Jennison Associates LLC increased its stake in Illumina, Inc. (NASDAQ:ILMN) by 19.1% in Q4, now holding 199,858 shares valued at approximately $26.21 million. Illumina reported strong Q1 results, beating EPS and revenue expectations, raising FY 2026 EPS guidance, and authorizing an additional $1.5 billion in share repurchases. While institutional ownership is high and the company shows growth in NovaSeq X demand, analyst sentiment remains mixed with a "Hold" consensus and an average price target of $130.13.
Earnings call transcript: Illumina beats Q1 2026 estimates, stock rises
Illumina Inc. reported stronger-than-expected Q1 2026 earnings, with both revenue ($1.09 billion) and non-GAAP EPS ($1.15) surpassing analyst estimates. This performance was driven by robust demand for sequencing consumables and instruments, particularly in clinical applications, leading to a 5.29% rise in after-hours trading. The company raised its full-year 2026 guidance, reflecting confidence in continued growth, especially in clinical markets, despite ongoing supply chain constraints and cautiousness in research sectors.
|Illumina (NASDAQ:ILMN) Posts Better-Than-Expected Sales In Q1 CY2026
|Illumina (NASDAQ:ILMN) reported strong Q1 CY2026 results, surpassing Wall Street's revenue and EPS expectations with sales up 4.8% year-on-year to $1.09 billion and non-GAAP profit exceeding estimates by 9%. The company also raised its full-year revenue and Adjusted EPS guidance. Despite a slight post-earnings stock dip, the company's efficient operations and promising outlook suggest a decent quarter for investors.
[8-K] ILLUMINA, INC. Reports Material Event
Illumina, Inc. (NASDAQ: ILMN) reported strong financial results for the first quarter of fiscal year 2026, with revenue up 4.8% to $1.09 billion and non-GAAP diluted EPS increasing to $1.15. The company also raised its full-year 2026 guidance for revenue to $4.52–$4.62 billion and non-GAAP EPS to $5.15–$5.30. Additionally, Illumina's board authorized a new $1.5 billion share repurchase program, demonstrating confidence in its business strategy and financial outlook.
Earnings Flash (ILMN) Illumina, Inc. Reports Q1 Revenue $1.09B, vs. FactSet Est of $1.07B
Illumina, Inc. (ILMN) reported Q1 revenue of $1.09 billion, exceeding FactSet's estimate of $1.07 billion. This announcement indicates stronger-than-expected financial performance for the quarter. The company also provided an updated outlook for fiscal year 2026.
Illumina Inc. stock outperforms competitors on strong trading day
Illumina Inc. (ILMN) saw its stock rally 5.29% to $126.74, outperforming the broader market indices like the S&P 500 and Dow Jones Industrial Average on a strong trading day. This increase ended a two-day losing streak for the company's shares.
Illumina Inc. Stock (US4523271090): Q1 2026 Earnings Release Expected Today
Illumina Inc. is scheduled to release its Q1 2026 earnings today, April 30, 2026, with investors keenly awaiting updates on core sequencing revenue and guidance. The report will shed light on the company's performance for the quarter ending March 31, 2026, following its full-year 2025 revenue of $4.5 billion. Market participants will be looking for confirmation or adjustments to the fiscal 2026 core consumables growth forecast and total revenue guidance.
Discipline and Rules-Based Execution in ILMN Response
This article provides an analysis of Illumina Inc. (NASDAQ: ILMN), highlighting weak near-term sentiment despite potential long-term strength. It details institutional trading strategies including long, momentum breakout, and short positions, along with multi-timeframe signal analysis for various horizons. The report emphasizes the discipline and rules-based execution recommended by AI models to optimize position sizing and minimize risk.
Illumina, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Financial Metrics
Illumina, Inc. has revised its stock valuation, demonstrating strong financial performance with a P/E ratio of 36, a PEG ratio of 0.64, and a robust ROCE of 28.32%. The company's one-year return of 64.77% significantly surpassed the S&P 500's performance, highlighting its competitive standing in the Pharmaceuticals & Biotechnology sector despite recent year-to-date fluctuations. These metrics indicate a favorable growth outlook and strong operational efficiency compared to its peers.
Illumina Inc. stock outperforms competitors despite losses on the day
Illumina Inc. (ILMN) shares fell 1.24% to $126.92 on Tuesday, despite the stock outperforming the broader market. The S&P 500 Index and Dow Jones Industrial Average also experienced losses during the trading session. This decline ended a two-day winning streak for Illumina Inc.
Illumina Inc. stock outperforms competitors on strong trading day
Illumina Inc. (ILMN) saw its stock advance by 1.95% to $127.88 on Friday, outperforming the broader market during a mixed trading session. This rise ended a four-day losing streak for the company. The S&P 500 Index rose, while the Dow Jones Industrial Average experienced a slight fall.
